Background/Aim: We performed a systematic review and meta-analysis to investigate the
safety of maintenance with olaparib after platinum-based chemotherapy in cancer patients …

Prostate cancer (PCa) mortality remains a significant public health problem, as advanced
disease has poor survivability due to the development of resistance in response to both …

Breast and ovarian cancer are common malignancies among older adults, causing
significant morbidity and mortality. Although most cases of breast and ovarian cancer are …

Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first
clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer …

Toxicity and emerging drug resistance pose important challenges in poly-adenosine ribose
polymerase inhibitor (PARPi) maintenance therapy of ovarian cancer. We propose that …

The poly (ADP-ribose) polymerase inhibitor olaparib (Lynparza™) is approved for
maintenance treatment of platinum-sensitive relapsed ovarian cancer. OPINION is a single …

Breast cancer is the most common type of cancer globally. Hereditary breast cancer
accounts for 10% of new cases and 4%–5% of cases are associated to pathogenic variants …

The present study investigated a combination of prostate cancer-targeting doxorubicin
(DOX) nanomicelles with photothermal therapy of castration-resistant prostate cancer …

Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of
olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after …

Purpose Olaparib was originally formulated as 50 mg capsules with a recommended dose of
400 mg twice daily which requires patients to take 16 capsules a day. More recently, a tablet …